Skip to main content
. 2023 Mar 22;4(4):100980. doi: 10.1016/j.xcrm.2023.100980

Figure 5.

Figure 5

Biomarker predictability in patient subgroups and explainability

(A) Internal validation ROCs for BRAF mutation prediction in the subgroup of MSI patients.

(B) Internal validation ROCs for BRAF status prediction in the subgroup of MSS patients.

(C) Internal validation ROCs for MSI/MSS status prediction in the subgroup of BRAF-mutated patients.

(D) Internal validation ROCs for MSI/MSS status prediction in the subgroup of BRAF wild-type patients.

(E and F) Top scoring tiles and Grad-CAM saliency maps for MSI (E) and MSS (F) status for the best in-domain Wang+attMIL model deployed on the DACHS cohort.

(G and H) Top scoring tiles for BRAF-mutated (G) and BRAF wild-type (H) status for the best in-domain Wang+attMIL model deployed on the DACHS cohort. For better interpretability, six out-of-focus tiles are not shown in this panel.

In (E)–(G), top tiles are the highest, top 5%, and top 10% scoring tiles in terms of the product of the tile’s attention and the tile’s classification score (left to right) for the patients with the highest overall classification score for the target mutation (top to bottom). High-resolution images can be found at Zenodo: https://doi.org/10.5281/zenodo.7454743. Correlation of prediction scores for MSI and BRAF status for the best image-only model can be found in Figure S6.